VivoSeq
Cardiovascular

After Cardiac Surgery

0

Pipeline Programs

10

Active Trials

1

Companies Involved

After Cardiac Surgery is an early-stage landscape with 0 programs across 1 company. The most active players are AM-Pharma.

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

80/100

Attrition Rate

11/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

65

clinical trials

Completed33 · 51%
Unknown status14 · 22%
Recruiting5 · 8%
Not yet recruiting4 · 6%
Terminated4 · 6%
Withdrawn3 · 5%
Other2 · 3%

Trial Activity

65 trials

Natriuresis-guided Depletion After Cardiac Surgery
Recruiting··N/A·NCT07077772·102 enrolled
Pain Management After Cardiac Surgery - Opioids or NSAID
Completed··Phase 4·NCT02479165·182 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)